Avidity
Ernest Chow is an accomplished professional in the biotechnology and pharmaceutical industries, currently serving as Senior Director of Portfolio Strategy at Avidity Biosciences, Inc., since September 2024. Previously, Chow held the position of Director of Global Product Strategy at Travere Therapeutics from January 2022 to December 2023, and prior to that, served as Director of Global Brand Management at BioMarin Pharmaceutical Inc., where roles included Associate Director and Senior Manager focused on rare diseases and business strategy. Chow began the career at PwC as a Senior Associate in Health Industries Advisory. Educational qualifications include an MBA from USC Marshall School of Business and a BS in Biochemistry and Cell Biology from UC San Diego.
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.